Toll-like receptor 4-Myeloid differentiation factor 2 complex (TLR4-MD-2) (TLR4-MD-2)

The Toll-like receptor 4-Myeloid differentiation factor 2 (TLR4-MD-2) complex is the primary sensing apparatus of the innate immune system for lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria (Park et al., 2009). TLR4 is a type I transmembrane protein that lacks the ability to bind LPS directly; instead, it relies on the extracellular protein MD-2 (also known as Lymphocyte Antigen 96) to capture the lipid A moiety of LPS (Shimazu et al., 1999). Upon binding, the TLR4-MD-2-LPS complex forms a symmetrical 'm'-shaped dimer, which brings the intracellular Toll/Interleukin-1 receptor (TIR) domains together to initiate downstream signaling via MyD88 and TRIF pathways (O'Neill et al., 2013). This signaling leads to the activation of transcription factors like NF-kappaB and IRF3, resulting in the production of pro-inflammatory cytokines and Type I interferons. While essential for host defense, overactivation of the TLR4-MD-2 complex is a central driver of septic shock and has been implicated in chronic conditions such as rheumatoid arthritis, atherosclerosis, and neuropathic pain (Kuzmich et al., 2017). Consequently, the complex is a major therapeutic target, with drug development focusing on antagonists like Eritoran to treat sepsis and agonists like Monophosphoryl lipid A (MPLA) for use as vaccine adjuvants (Needham et al., 2013).

Other names

TLR4-MD2 complexLPS receptor complexCD284-LY96 complexToll-like receptor 4-Lymphocyte antigen 96 complexTLR4/MD-2 heterodimer

Antagonists of the TLR4-MD-2 complex, such as Eritoran, bind to the hydrophobic pocket of MD-2, competitively inhibiting the binding of the lipid A portion of lipopolysaccharide (LPS) and preventing the dimerization of the TLR4-MD-2 complex. Intracellular inhibitors like Resatorvid bind to the TIR domain of TLR4 to disrupt adapter protein recruitment. Conversely, agonists like Monophosphoryl lipid A (MPLA) mimic the structure of lipid A to induce a controlled activation of the complex, often biased toward the TRIF pathway, which is utilized in vaccine adjuvancy to stimulate immune memory without excessive systemic inflammation.